Spanish Cardiologists Release Gender-Specific CV Guide

Age-Specific Risks

The guidelines highlight age-specific CV risks for women.

  • In adolescent girls (10-21 years of age), key risk factors include a higher fat-to-lean mass ratio than that in boys (25% vs 14%), reduced physical activity, and higher smoking rates.
  • In women aged over 21 years, conditions such as polycystic ovary syndrome (PCOS), hypogonadotropic hypogonadism, and premature ovarian insufficiency (POI), all characterised by oestrogen deficiency, significantly increase CV risk. These hormonal imbalances are linked to metabolic disorders such as insulin resistance, central obesity, dyslipidaemia, and hypertension.
  • Menopause is associated with oestrogen production, leading to metabolic changes, including central abdominal fat accumulation, obesity, sarcopenia, and dyslipidaemia, which increase the risk for myocardial infarction and cerebrovascular events.

Hormone replacement therapy (HRT) is recommended for premenopausal women with POI or hypogonadotropic hypogonadism if there are no contraindications. Transdermal oestrogens have a more favourable impact on CV risk biomarkers than oral formulations.

Menopause is associated with reduced CV protection due to decreased oestrogen production. Metabolic changes during this phase, including central abdominal fat accumulation, obesity, sarcopenia, and dyslipidaemia, increase the risk for myocardial infarction and cerebrovascular events, particularly in cases of early menopause.

Recent studies have found HRT to be the most effective intervention for symptom relief and improved quality of life. These measures can reduce CVD risk and all-cause mortality in women aged under 60 years and within 10 years of menopause onset. However, HRT is not recommended for patients with high CV risk or pre-existing CVD.

Pregnancy Risks

Pregnancy causes significant CV changes, necessitating close monitoring. In women with pre-existing cardiometabolic risk factors or genetic or environmental predispositions, the physiological stress of pregnancy can lead to adverse outcomes, such as hypertensive disorders, intrauterine growth restriction, small-for-gestational-age neonates, placental abruption, preterm birth, and gestational diabetes mellitus (GDM). Women with a history of adverse pregnancy outcomes have a higher long-term risk for CVD.

Pre-pregnancy evaluations and early detection during weeks 11-13 of pregnancy are critical for identifying CV risks. Hypertensive disorders affect 10% of pregnant women, and GDM is another significant risk factor.

Additional Risks

Classic CV risk factors in women include smoking, obesity, hypertension, diabetes, and dyslipidaemia. Additional factors included:

  • Breast cancer survivors face higher risks for heart failure and myocardial ischaemia due to latent cardiac effects from cancer treatments.
  • Psychosocial stress: Strongly associated with the development and progression of CV atherosclerosis.
  • Autoimmune diseases: Conditions such as systemic lupus erythematosus and rheumatoid arthritis significantly increase the risk for CV disease.

 

https://www.medscape.com/viewarticle/spanish-cardiologists-release-gender-specific-cv-guide-2025a10008ro

 

 

Scientific news

  • Engineered blood clots stop bleeding in seconds The blood in the vascular system of the body supports vital functions, but when it leaves the body, it must quickly form a strong protective barrier — a clot that prevents death. However, because natural blood clots are known to form very slowly, heavy bleeding from accidents, battlefield injuries, and surgical complications leads to many potentially preventable deaths. In an article for the journal Nature, Jiang et al. They talked about the achievements of bioengineering that solve this problem by fundamentally changing the structure of blood clots.
  • Cardiac resynchronisation therapy among adults with a systemic right ventricle: a multicentre experience Researchers conducted an international retrospective study including patients over 18 years of age from 33 centers with transposition of the great arteries (TGA) after atrial switch surgery and congenitally corrected TGA.
  • Cardiovascular disease in Sickle cell: mechanisms, diagnostics and therapeutic advances Cardiovascular complications are increasingly recognized as a major cause of morbidity and early mortality in patients with sickle cell disease, yet they remain underdiagnosed and underestimated. In a new review, the authors summarize current knowledge on a wide range of cardiovascular manifestations, including myocardial dysfunction, pulmonary hypertension, cardiac iron overload, arrhythmia, myocardial infarction, stroke, and sudden death, with an emphasis on their unique pathophysiological mechanisms in Wolf-Hirschhorn syndrome.
  • Parsimonious machine learning model to predict 1-year mortality and procedural futility after transcatheter aortic valve replacement Current risk assessment scores are insufficiently accurate in predicting long-term mortality after transcatheter aortic valve replacement, limiting their usefulness for decision-making regarding the feasibility of the procedure. The researchers aimed to develop and test a machine learning model on external data using only preoperative variables to predict all-cause mortality within one year.
  • Congenital heart disease in England: a national cohort study from fetal diagnosis to end of infancy Population-based studies of congenital heart defects (CHDs) often include only children who have undergone cardiac surgery, leading to an underestimation of the number of cases that do not require intervention. In a new study, the authors analyzed the outcomes of all identified cases of structural CHDs in England from prenatal to one year of age.

Partners

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru